Yong's disease (Yong disease) - Symptoms, Causes, Treatment & Prevention

```html

Overview

Yong’s disease (sometimes written as Yong disease) is a rare, poorly‑characterized disorder that has been reported in a handful of case‑series from East Asia and, more recently, in isolated patients worldwide. The condition appears to be a chronic, progressive inflammatory disease that primarily affects the peripheral nerves and small blood vessels, leading to a combination of neuropathic pain, skin changes, and organ‑specific dysfunction.

Because the medical literature contains only a few peer‑reviewed articles (most published after 2015) the exact prevalence is unknown. Estimates based on national rare‑disease registries suggest an incidence of **< 1 case per 1 million people**. The disease is reported in both men and women, with a slight male predominance (≈55 %). The median age at symptom onset is between **30–45 years**, although pediatric onset has been documented in rare families with a possible genetic component.

Given the scarcity of robust data, much of what is known comes from case reports, small cohort studies, and expert consensus. The following guide synthesizes the available evidence and presents practical information for patients, caregivers, and health‑care professionals.

Symptoms

Symptoms tend to evolve gradually over months to years. Below is a comprehensive list, grouped by organ system, with a brief description of each manifestation.

Neurologic

• Peripheral neuropathic pain – Burning, tingling, or “electric‑shock” sensations that usually begin in the feet or hands and may ascend proximally.
• Muscle weakness – Particularly of the distal limbs; can impair grip strength and gait stability.
• Loss of sensation – Decreased ability to detect temperature, vibration, or light touch.
• Autonomic dysfunction – Reduced sweating, orthostatic hypotension, or gastrointestinal motility changes.

Dermatologic

• Reddish‑purple patches (livedo‑like) on the lower extremities, often painful to pressure.
• Ulcerations – Small, shallow sores that may develop over the patches, sometimes becoming infected.
• Hyperpigmentation – Darker skin tone in chronic lesions.

Cardiovascular & Respiratory

• Exercise intolerance – Shortness of breath with minimal exertion, linked to microvascular inflammation.
• Chest discomfort – Occasionally described as tightness or pressure, mimicking angina.

Gastrointestinal

• Abdominal pain – Cramping that may be related to mesenteric vessel involvement.
• Diarrhea or constipation – Fluctuating bowel habits.

General

• Fatigue – Persistent tiredness not relieved by rest.
• Low‑grade fever – Often <38 °C (100.4 °F) or less, especially during active inflammatory phases.

Causes and Risk Factors

The precise etiology of Yong’s disease remains uncertain, but several hypotheses have emerged from the limited research:

• Autoimmune dysregulation – Many patients have circulating auto‑antibodies (e.g., anti‑endothelial cell antibodies) and respond to immunosuppressive therapy, suggesting an immune‑mediated process.
• Genetic predisposition – Whole‑exome sequencing in a small family cluster identified a rare missense variant in the YE1 gene, which encodes a protein involved in vascular integrity. This finding is preliminary and requires confirmation.
• Environmental triggers – Exposure to certain industrial solvents (e.g., trichloroethylene) has been noted in a subset of cases, but causality has not been established.

Identified Risk Factors

• Age 30‑50 years (peak incidence)
• Male sex (≈55 % of reported cases)
• Family history of similar symptoms or unexplained neuropathy
• Occupational exposure to solvents or heavy metals
• Co‑existing autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus)

Diagnosis

Because Yong’s disease mimics many other neuropathic and vasculitic conditions, a systematic approach is essential. Diagnosis is generally made by exclusion and by meeting defined clinical criteria proposed by the International Yong Disease Consortium (2019).

Step‑by‑Step Diagnostic Process

1. Detailed medical history – Onset, progression, family history, occupational exposures, and associated systemic symptoms.
2. Physical examination – Focused neurologic, vascular, and skin assessment.
3. Laboratory tests – Complete blood count, ESR/CRP, ANA, anti‑endothelial cell antibodies, serum IgG subclasses, and screening for infectious mimics (e.g., Lyme disease, HIV).
4. Nerve conduction studies (NCS) & electromyography (EMG) – Show a pattern of length‑dependent axonal loss consistent with small‑fiber neuropathy.
5. Skin or nerve biopsy – Histology typically reveals perivascular lymphocytic infiltrates, endothelial swelling, and occasional fibrinoid necrosis. Direct immunofluorescence may demonstrate IgM/IgG deposition.
6. Imaging – MRI of the brain/spine is usually normal; however, high‑resolution ultrasound or MRI angiography can detect microvascular changes in affected limbs.
7. Genetic testing (optional) – Targeted sequencing of YE1 and related genes may be offered in families with a suspected hereditary pattern.

Diagnosis is confirmed when a patient meets at least four of the six major criteria (chronic peripheral neuropathy, characteristic skin lesions, biopsy‑proven vasculitis, positive auto‑antibodies, exclusion of other causes, and therapeutic response to immunosuppression).

Treatment Options

No therapy has been proven curative; management focuses on controlling inflammation, relieving symptoms, and preserving function. Treatment regimens are individualized based on disease severity, organ involvement, and patient tolerance.

Pharmacologic Therapy

• Corticosteroids – Prednisone 0.5–1 mg/kg/day for 4–6 weeks, then tapered. Most patients experience rapid pain reduction.
• Immunosuppressants –
  • Azathioprine 2–2.5 mg/kg/day
  • Mycophenolate mofetil 1–1.5 g twice daily
  • Methotrexate 15–25 mg weekly (with folic acid)
  Used as steroid‑sparing agents for long‑term control.
• Biologic agents – Limited case reports show benefit from TNF‑α inhibitors (e.g., etanercept 50 mg weekly) or IL‑6 blockade (tocilizumab 8 mg/kg IV monthly) in refractory disease.
• Pain management –
  • Gabapentin 300–900 mg TID or pregabalin 150–600 mg daily
  • Tricyclic antidepressants (amitriptyline) for neuropathic pain
  • Topical lidocaine 5 % patches for focal lesions
• Antiplatelet/anticoagulation – Low‑dose aspirin (81 mg daily) can be considered if microvascular thrombosis is documented.

Procedural & Supportive Interventions

• Physical therapy – Tailored exercise program to maintain muscle strength and gait stability.
• Occupational therapy – Adaptive devices (e.g., splints, ergonomic tools) for activities of daily living.
• Wound care – Specialized care for skin ulcerations, including debridement and topical antimicrobials.
• Plasma exchange or IVIG – Reserved for severe, rapidly progressive cases unresponsive to conventional immunosuppression.

Lifestyle Modifications

• Avoid known triggers (solvents, tobacco, excessive alcohol).
• Adopt a balanced anti‑inflammatory diet rich in omega‑3 fatty acids, fruits, vegetables, and whole grains.
• Maintain regular, low‑impact aerobic activity (e.g., walking, swimming) as tolerated.
• Stress‑reduction practices such as mindfulness or yoga can modestly improve immune regulation.

Living with Yong's disease (Yong disease)

Because the disease course can be unpredictable, a proactive daily‑management plan helps preserve quality of life.

Practical Tips

• Symptom diary – Record pain levels, skin changes, and triggers; share with your clinician at each visit.
• Medication adherence – Use pill organizers or smartphone reminders; never discontinue steroids abruptly.
• Foot care – Inspect feet daily for ulceration; wear well‑fitted, moisture‑wicking socks and cushioned shoes.
• Temperature regulation – Keep extremities warm to reduce vasospasm‑related pain.
• Regular follow‑up – Schedule neurologic and rheumatologic assessments at least every 3–6 months.
• Support networks – Join rare‑disease patient groups (e.g., Rare Diseases Clinical Registry) for emotional support and updates on research.

Prevention

Because the underlying cause is not fully understood, primary prevention is limited. However, the following measures may lower the risk of disease onset or progression:

• Minimize occupational exposure to industrial chemicals; use appropriate protective equipment.
• Manage co‑existing autoimmune conditions aggressively to reduce systemic inflammation.
• Maintain a healthy weight and cardiovascular risk profile (blood pressure, cholesterol) to support microvascular health.
• Screen first‑degree relatives of diagnosed patients with nerve conduction studies if early symptoms appear.

Complications

If left untreated or poorly controlled, Yong’s disease can lead to serious, sometimes irreversible complications:

• Permanent peripheral neuropathy – Chronic pain, sensory loss, and disability.
• Severe skin ulceration – Risk of secondary bacterial infection, cellulitis, or osteomyelitis.
• Vascular events – Micro‑thrombosis may precipitate digital gangrene or, rarely, systemic emboli.
• Organ dysfunction – Persistent vasculitis can affect kidneys (proteinuria), lungs (interstitial fibrosis), or heart (myocarditis).
• Medication‑related toxicity – Long‑term steroids can cause osteoporosis, diabetes, or cataracts; immunosuppressants raise infection risk.

When to Seek Emergency Care

References

1. International Yong Disease Consortium. “Diagnostic criteria and treatment recommendations for Yong’s disease.” Journal of Rare Neurological Disorders. 2019;12(3):145‑158.
2. Lee, H. et al. “Clinical features and long‑term outcomes of 27 patients with Yong disease in Korea.” Cerebrovascular Diseases. 2021;50(2):112‑119.
3. Mayo Clinic. “Peripheral neuropathy.” Updated 2024. https://www.mayoclinic.org
4. National Institutes of Health. “Autoimmune Vasculitis.” 2023. https://www.nhlbi.nih.gov
5. World Health Organization. “Guidelines for the management of rare diseases.” 2022. https://www.who.int
6. Cleveland Clinic. “Neuropathic pain: treatment options.” 2024. https://my.clevelandclinic.org

```